Clinical Trial Update: Colistin and Rifampicin for MDR-Acinetobacter [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating colistin plus rifampicin for multidrug-resistant Acinetobacter infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bloodstream Infection
• Hospital-acquired Pneumonia
• Intra-abdominal Infection
• Ventilator-associated Pneumonia

Drugs mentioned

• Colistin (colistin)
• Rifampicin

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Infection Due to Resistant Bacteria, Pneumonia, Ventilator-Associated | Phase 3 | Status: COMPLETED